Finding ways to overcome resistance to ibrutinib in mantle cell lymphoma
Overcoming ibrutinib resistance in mantle cell lymphoma
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-11017849
This study is looking at why some people with mantle cell lymphoma stop responding to the drug ibrutinib, focusing on a protein called NFκB, to find ways to help those who aren't getting better with current treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-11017849 on ClinicalTrials.gov |
What this research studies
This research investigates how some patients with mantle cell lymphoma develop resistance to the drug ibrutinib, which is used to treat certain types of blood cancers. The study focuses on understanding the role of a protein called NFκB and its signaling pathways in this resistance. By examining tumor samples and the surrounding microenvironment, researchers aim to identify mechanisms that contribute to treatment failure. The goal is to develop strategies to improve outcomes for patients who do not respond to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who have experienced resistance to ibrutinib treatment.
Not a fit: Patients with mantle cell lymphoma who have not been treated with ibrutinib or those with other types of blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with mantle cell lymphoma who are resistant to ibrutinib.
How similar studies have performed: Previous research has shown that targeting NFκB pathways can be effective in other cancers, suggesting potential for success in this area as well.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DANILOV, ALEXEY V. — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: DANILOV, ALEXEY V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.